Ventracor Administrators Favor Sale To U.S.-based Siqro
This article was originally published in PharmAsia News
Executive Summary
Administrators of Australia's Ventracor, a maker of medical devices, have recommended the company's creditors support selling the company rather than accepting a shareholder solution. U.S.-based Siqro has offered to buy Ventracor's assets and the administrators said that was the better offer. Siqro wants to market Ventracor's VentrAssist heart pump in the United States, and the administrators feel its offer would give creditors full payment of what they are owed. A shareholder group promotes raising funds to make the purchase possible, but administrators questioned the availability of post-sale funds. (Click here for more
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.